PubMed Health⌕ Search

Biomedical subjects

P Hendry

Publications and source records attributed to P Hendry.

6 recordsLinked to original sources
PubMed1992

A ribozyme with DNA in the hybridising arms displays enhanced cleavage ability.

Hammerhead ribozymes cleave RNA substrates containing the UX sequence, where X = U, C or A, embedded within sequences which are complementary to the hybridising 'arms' of the ribozyme. In this study we have replaced the RNA in the hybridising arms of the ribozyme with DNA, and the resulting ribozyme is many times more active than its precursor. In turnover-kinetics experiments with a 13-mer RNA substrate, the kcat/Km ratios are 10 and 150 microM-1min-1 for the RNA- and DNA-armed ribozymes, respectively. The effect is due mainly to differences in kcat. In independent experiments where the cleavage step is rate-limiting, the DNA-armed ribozyme cleaves the substrate with a rate constant more than 3 times greater than the all-RNA ribozyme. DNA substrates containing a ribocytidine at the cleavage site have been shown to be cleaved less efficiently than their all-RNA analogues; again however, the DNA-armed ribozyme is more effective than the all-RNA ribozyme against such DNA substrates. These results demonstrate that there are no 2'-hydroxyl groups in the arms of the ribozyme that are required for cleavage; and that the structure of the complex formed by the DNA-armed ribozyme with its substrate is more favourable for cleavage than that formed by the all-RNA ribozyme and its substrate.

Animals↗
PubMed1992

Minimal sequence requirements for ribozyme activity.

The hammerhead ribozyme, as engineered by J. Haseloff and W. L. Gerlach [(1988) Nature (London) 334, 585-591], is an RNA molecule containing two regions of conserved nucleotides, a double helix, called helix II, which connects the two conserved regions, and flanking arms of variable sequence, which hybridize the ribozyme to its specific target. Here we show that this ribozyme may be reduced in size and still retain cleavage activity by replacing helix II with just a few nucleotides that cannot form Watson-Crick base pairs between themselves. Furthermore, the nucleotides replacing helix II and the nucleotides in the flanking arms may be substituted with DNA, and this small, DNA-containing ribozyme is fully as active as the original, full-size ribozyme. Cleavage activity of the minimized ribozyme depends on the number and sequence of the few nucleotides that replace helix II; optimal activity, thus far, is achieved by four or five deoxyribopyrimidines. The minimized ribozyme, or "minizyme," is active as a monomer, as shown by its nearly constant activity over a concentration range varying 25,000-fold, by the mobility of the minizyme-substrate complex in nondenaturing polyacrylamide gels as compared with other nucleic acid molecules of known size, and by other observations. These minizymes provide an excellent model system for studying the structure and mechanism of catalytic RNA; they might also be useful in a variety of biological applications.

Base Sequence↗
PubMed1990

Modified bacteriophage lambda promoter vectors for overproduction of proteins in Escherichia coli.

A new series of expression vectors that direct high-level overproduction of gene products in Escherichia coli is described. All contain strong bacteriophage lambda promoters, PR and PL, arranged in tandem so that both promote transcription into genes inserted into or between unique restriction sites. The vectors also direct expression of the lambda cI857 gene (from its natural promoter, PM), which enables their use in any E. coli host strain to effect controlled expression by shifting the temperature of cultures from 30 to 42 degrees C. The vectors pCE30, pND201, pPT150 and pMA200U are derivatives of the high-copy-number plasmid pUC9. Vector pCE33 is an analogous derivative of the heat-inducible runaway-replication plasmid, pMOB45, and directs overproduction of proteins by virtue of increase in both gene dosage and transcription following treatment at 42 degrees C. The vectors pND201 and pPT150 bear a ribosome-binding site (RBS) perfectly complementary to the 3' end of E. coli 16-S rRNA a few bp upstream from a unique HpaI site. Ways in which they may be used to improve the efficiency of translation of mRNA by substitution of a natural RBS with selection for optimal spacing from an ATG (or GTG) start codon are described. The phagemid vector pMA200U is a direct analog of pCE30 designed to facilitate preparation of single-stranded DNA templates for use in oligodeoxyribonucleotide-directed mutagenesis of overexpressed genes.

Bacteriophage lambda↗
PubMed1988

Coronary endarterectomy. An adjunct to coronary artery bypass grafting.

There is a wide variation in the reported results of endarterectomy in conjunction with coronary artery bypass grafting. Operative mortality ranges from 0 to 10 per cent, perioperative infarction ranges from 5 to 30 per cent, and patency rates range from 38 to 100 per cent, with 74 to 95 per cent being asymptomatic or improved. This wide discrepancy in clinical outcome occurs for a number of reasons. First, there is nonhomogeneity of patient populations resulting from a lack of standardized patient selection criteria. Second, the operative experience of most published reports spans a decade throughout which major advances in cardiac surgery have occurred. Finally, endarterectomy is a technically challenging procedure with its own learning curve. Differences in technique and expertise almost certainly contribute to the variability of results. Patients with diffuse coronary artery disease pose a challenge to the cardiac surgeon. Endarterectomy entails the risks of increased morbidity and mortality and therefore should be done only if conventional bypass grafting is precluded. However, the risks of these complications must always be weighed against the possible benefits. At the present time carefully selected patients can benefit from this procedure. Unfortunately, until such time as controlled randomized studies are carried out on a prospective basis, statistical support for this procedure will not be available. Given that such a study is questionable from an ethical point of view, clinical decisions for this select group of patients must be done on a case-by-case basis. The best that can currently be done is to carefully follow these patients and scrutinize existing data to ensure optimal clinical management.

Coronary Artery Bypass↗